LBA11 IPSOS: Results from a phase III study of first-line (1L) atezolizumab (atezo) vs single-agent chemotherapy (chemo) in patients (pts) with NSCLC not eligible for a platinum-containing regimen

Siow Ming Lee, Christian Schulz, K. Prabhash, Bei Han, Aleksandra Szczęsna, D.L. Cortinovis, A. Rittmeyer, David Vicente Baz, Raffaele Califano, Le Tuan Anh, G. Liu, F. Cappuzzo, J.G. Reyes Contreras, M. Reck, Youyou Hu, S. Morris, E.K. Hoeglander, M. Connors, Hans Kristian Moen Vollan, Solange Peters